AstraZeneca, breast cancer
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...
Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia. The biotechnology company also said Thursday it ...
A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...
2h
Alla Pinzour says she's a trouper. She has lived with melanoma for 15 years. A new therapy offered at the University of ...
Learn how Oracle Cloud Infrastructure and its cutting-edge AI features are bringing new benefits to cancer care by helping ...
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...
Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback